title: Type-specific HPV testing as a predictor of high-grade squamous intraepithelial lesion outcome after cytologic abnormalities.
abstract: OBJECTIVE
  Human papillomavirus (HPV) risk assignment influences management after a cytologic diagnosis of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL). This study addressed whether type-specific HPV testing predicts risk of biopsy outcome of high-grade cervical intraepithelial neoplasia (CIN 2,3).
  
  
  METHODS
  A total of 162 ASCUS or LSIL diagnoses with colposcopic follow-up were evaluated and placed in 3 groups: Analysis 1: (high-risk HPVs including types 53 and 66; Analysis 2 (high-risk HPVs excluding types 53 and 66); and Analysis 3 (high-risk HPVs including type 53 and excluding type 66).
  
  
  RESULTS
  CIN 2,3 biopsy results followed low-risk HPVs in 0%, 3%, and 0% of scenarios 1, 2, and 3, respectively; 21%, 40%, and 27% of smears were classified as low risk, respectively. Of HPV 53 infections, 13.6% had CIN 2,3 biopsy outcomes.
  
  
  CONCLUSIONS
  Type-specific HPV testing accurately classifies a group of HPV-positive LSIL/ASCUS cases at low risk for CIN 2,3 at the first follow-up visit. Classifying HPV 53 as low-risk increases slightly the proportion of HSIL outcomes in the low-risk group, but may not increase cancer risk. HPV 53 merits designation as a high-risk HPV based only [corrected] on the proportion of CIN 2,3 in follow-up biopsy.
authors.affiliation: Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02130, USA.
authors.forename: Fabiola
authors.initials: F
authors.lastname: Medeiros
authors.forename: Liping
authors.initials: L
authors.lastname: Yuan
authors.forename: Gillian
authors.initials: G
authors.lastname: Breslin
authors.forename: Joshua
authors.initials: J
authors.lastname: Brodsky
authors.forename: Ashraf
authors.initials: A
authors.lastname: Saleemuddin
authors.forename: Sarah
authors.initials: S
authors.lastname: Feldman
authors.forename: Lynda
authors.initials: L
authors.lastname: Rushing
authors.forename: Aida
authors.initials: A
authors.lastname: Cviko
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Lee
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Crum
mesh_terms: D001706:Biopsy; D002584:Cervix Uteri / Q000473:pathology*; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000145:classification* / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000150:complications*; D011237:Predictive Value of Tests; D012306:Risk; D018570:Risk Assessment; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000473:pathology* / Q000821:virology